AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34911566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions combined
Number of subjects: 40
Study 36367144 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc for 15 days
Number of subjects: 470
Study 36367144 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 470
Study 34656194 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical competence
Number of subjects: 38
Study 34656194 — intervention group
Group type: EXPERIMENTAL
Intervention: Global competence
Number of subjects: 38
Study 34656194 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical and global competence
Number of subjects: 38
Study 33093036 — intervention group
Group type: EXPERIMENTAL
Intervention: HRQoL (EuroQol EQ-5D-3L) after 6 months
Number of subjects: 502
Study 33093036 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcome of falls, hospitalisation, institutionalisation and nursing care needs after 6, 9, and 24 months (claims data)
Number of subjects: 502
Study 35112504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 701
Study 35112504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (3, 7, or 14 mg)
Number of subjects: 701
Study 35112504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 35112504 — intervention group
Group type: COMPARATOR
Intervention: Once-daily subcutaneous liraglutide 0.9 mg
Number of subjects: 701
Study 35112504 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly subcutaneous dulaglutide 0.75 mg
Number of subjects: 701
Study 34484560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary valine at 0.59%
Number of subjects: 960
Study 34484560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary valine at 0.64%
Number of subjects: 960
Study 34484560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary valine at 0.69%
Number of subjects: 960
Study 34484560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary valine at 0.74%
Number of subjects: 960
Study 34484560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary valine at 0.79%
Number of subjects: 960
Study 34254577 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer instructors trained by health professionals (Group A)
Number of subjects: 0
Study 34254577 — intervention group
Group type: COMPARATOR
Intervention: Peer instructors trained by their peers (Group B)
Number of subjects: 0
Study 32580579 — intervention group
Group type: EXPERIMENTAL
Intervention: Infigratinib
Number of subjects: 0
Study 32580579 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (gemcitabine and cisplatin)
Number of subjects: 0
Study 35857356 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured supervised exercise training (EXE)
Number of subjects: 220
Study 35857356 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counseling (MOT)
Number of subjects: 220
Study 35857356 — intervention group
Group type: COMPARATOR
Intervention: Standard care (CON)
Number of subjects: 220
Study 33610115 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide + folic acid (group-I)
Number of subjects: 45
Study 33610115 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea + folic acid (group-II)
Number of subjects: 45
Study 33610115 — intervention group
Group type: COMPARATOR
Intervention: Folic acid only (group-III)
Number of subjects: 45
Study 33296467 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber breakfast cereals (>3.5 g/portion)
Number of subjects: 272
Study 33296467 — intervention group
Group type: COMPARATOR
Intervention: Low-fiber breakfast cereals (<1.0 g/portion)
Number of subjects: 272
Study 32407835 — intervention group
Group type: EXPERIMENTAL
Intervention: RPC4046 180 mg
Number of subjects: 69
Study 32407835 — intervention group
Group type: EXPERIMENTAL
Intervention: RPC4046 360 mg
Number of subjects: 69
Study 32407835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 35969196 — intervention group
Group type: EXPERIMENTAL
Intervention: Friction group using elastomeric power chains
Number of subjects: 30
Study 35969196 — intervention group
Group type: COMPARATOR
Intervention: Frictionless group using T‐loop springs
Number of subjects: 30
Study 35969196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 33407371 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental intervention combined with dietary and exercise guidance
Number of subjects: 112
Study 32407947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy with allergenic extract
Number of subjects: 21
Study 32407947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 35710253 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot capsules (500 mg three times a day for 4 weeks)
Number of subjects: 90
Study 35710253 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot plus vitamin C capsules (500 mg three times a day for 4 weeks)
Number of subjects: 90
Study 35710253 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (three times a day for 4 weeks)
Number of subjects: 90
Study 32987146 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary intravascular shunts (TIVS)
Number of subjects: 691
Study 32987146 — intervention group
Group type: COMPARATOR
Intervention: Management without TIVS (Control)
Number of subjects: 691
Study 32621736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose water (10 g of glucose in 100 ml of warm water, 5 ml/kg) 1 hour before surgery
Number of subjects: 344
Study 32621736 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose water (10 g of glucose in 100 ml of warm water, 5 ml/kg) 2 hours before surgery
Number of subjects: 344
Study 35943471 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban
Number of subjects: 948
Study 35943471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 948
Study 34264500 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 0
Study 34264500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32052740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing (SDB) screening
Number of subjects: 390
Study 32052740 — intervention group
Group type: EXPERIMENTAL
Intervention: Malocclusion (anterior open bite)
Number of subjects: 390
Study 32052740 — intervention group
Group type: EXPERIMENTAL
Intervention: Malocclusion (posterior crossbite)
Number of subjects: 390
Study 32052740 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 390
Study 36564877 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular soy formula intake (≥14 days per month and ≥1350 ml per month)
Number of subjects: 235
Study 32134394 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention tailored to individual values and beliefs regarding vaccinations
Number of subjects: 41
Study 32134394 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 41
Study 34143996 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST only
Number of subjects: 4544
Study 34143996 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST plus financial incentive
Number of subjects: 4544
Study 34143996 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4544
Study 32195640 — intervention group
Group type: EXPERIMENTAL
Intervention: ILIB-100 mW, 660 ± 10 nm, 30 applications in total, divided into 3 stages of 10 applications, 30 min each, daily, with a 20‐day interval between each stage
Number of subjects: 30
Study 32195640 — intervention group
Group type: COMPARATOR
Intervention: Control - conventional treatment
Number of subjects: 30
Study 32195640 — intervention group
Group type: COMPARATOR
Intervention: SILIB - same protocol as ILIB but with equipment switched off
Number of subjects: 30
Study 33290875 — intervention group
Group type: COMPARATOR
Intervention: Topiramate 0 mg/day + Phentermine 0 mg
Number of subjects: 31
Study 33290875 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day + Phentermine 15 mg
Number of subjects: 31
Study 33290875 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day + Phentermine 30 mg
Number of subjects: 31
Study 33290875 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day + Phentermine 15 mg
Number of subjects: 31
Study 33290875 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day + Phentermine 30 mg
Number of subjects: 31
Study 33290875 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate and Phentermine combined
Number of subjects: 31
Study 32175638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical compression using the Cirvo device
Number of subjects: 15
Study 32175638 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic compression using VenaFlow system
Number of subjects: 15
Study 32175638 — intervention group
Group type: COMPARATOR
Intervention: Manual calf compression
Number of subjects: 15
Study 37698371 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6-genotype-guided opioid selection
Number of subjects: 85
Study 37698371 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 85
Study 33459908 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatment in PLA2R-positive patients
Number of subjects: 201
Study 33459908 — intervention group
Group type: EXPERIMENTAL
Intervention: THSD7A-positive MN treatment
Number of subjects: 201
Study 33459908 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA2R-positive MN
Number of subjects: 201
Study 33459908 — intervention group
Group type: COMPARATOR
Intervention: PLA2R-negative MN
Number of subjects: 201
Study 32942730 — intervention group
Group type: EXPERIMENTAL
Intervention: DAid smart shirt system
Number of subjects: 0
Study 32942730 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 0
Study 35400993 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB) 6 mL·h‐1 of 0.1% ropivacaine
Number of subjects: 120
Study 35400993 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (CEI) 6 mL·h‐1 of 0.1% ropivacaine
Number of subjects: 120
Study 33977775 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional intelligence skills training (4 sessions)
Number of subjects: 30
Study 33977775 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 32358376 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiaotai pill (JTP) plus fluoxetine
Number of subjects: 40
Study 32358376 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine alone
Number of subjects: 40
Study 36034810 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiedu Tongluo Tiaogan Formula (JTTF) + conventional basic treatment
Number of subjects: 98
Study 36034810 — intervention group
Group type: COMPARATOR
Intervention: Conventional basic treatment
Number of subjects: 98
Study 33169409 — intervention group
Group type: EXPERIMENTAL
Intervention: cilofexor/firsocostat
Number of subjects: 392
Study 33169409 — intervention group
Group type: EXPERIMENTAL
Intervention: cilofexor/selonsertib
Number of subjects: 392
Study 33169409 — intervention group
Group type: EXPERIMENTAL
Intervention: firsocostat/selonsertib
Number of subjects: 392
Study 33169409 — intervention group
Group type: EXPERIMENTAL
Intervention: firsocostat
Number of subjects: 392
Study 33169409 — intervention group
Group type: EXPERIMENTAL
Intervention: cilofexor
Number of subjects: 392
Study 33169409 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 392
Study 34083113 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol patch therapy
Number of subjects: 240
Study 34083113 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study 34083113 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery time of 250 min or more
Number of subjects: 240
Study 33000587 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint therapy combined with spine pinching
Number of subjects: 132
Study 33000587 — intervention group
Group type: COMPARATOR
Intervention: Tibolone therapy alone
Number of subjects: 132
Study 36189824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates training
Number of subjects: 45
Study 36189824 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua-Pilates training
Number of subjects: 45
Study 36189824 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 33516195 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric intervention and exercise (preoperative CGA, perioperative geriatric in‐ward review, postoperative follow‐up, resistance exercise program twice/week for 2+12 weeks)
Number of subjects: 100
Study 33516195 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric intervention and exercise
Number of subjects: 100
Study 33516195 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 100
Study 32566276 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic banded sleeve gastrectomy (LBSG)
Number of subjects: 50
Study 32566276 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 50
Study 33728742 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy training in addition to usual care
Number of subjects: 275
Study 33728742 — intervention group
Group type: COMPARATOR
Intervention: Control condition in addition to usual care
Number of subjects: 275
Study 33574145 — intervention group
Group type: EXPERIMENTAL
Intervention: Concussion Essentials (CE), a multimodal, interdisciplinary delivered, symptom‐tailored treatment involving physiotherapy, psychology, and education, 1 hour per week for up to 8 weeks or until pPCS resolve.
Number of subjects: 216
Study 33574145 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 216
Study 33574145 — intervention group
Group type: EXPERIMENTAL
Intervention: Concussion Essentials (CE)
Number of subjects: 216
Study 32695314 — intervention group
Group type: EXPERIMENTAL
Intervention: TFESI plus CESI (TC group)
Number of subjects: 54
Study 32695314 — intervention group
Group type: COMPARATOR
Intervention: TFESI alone (T group)
Number of subjects: 54
Study 35674176 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet technology and animated videos
Number of subjects: 26
Study 32361934 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose HSYAI (50 mg/d)
Number of subjects: 266
Study 32361934 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose HSYAI (70 mg/d)
Number of subjects: 266
Study 32361934 — intervention group
Group type: COMPARATOR
Intervention: Control group (Dengzhan Xixin Injection, 30 mL/d)
Number of subjects: 266
Study 34783404 — intervention group
Group type: EXPERIMENTAL
Intervention: SCR + aPDT
Number of subjects: 64
Study 34783404 — intervention group
Group type: COMPARATOR
Intervention: SCR
Number of subjects: 64
Study 34558154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography (CBCT)
Number of subjects: 34
Study 34558154 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D CBCT-based planning software
Number of subjects: 34
Study 34558154 — intervention group
Group type: EXPERIMENTAL
Intervention: Periapical radiographs
Number of subjects: 34
Study 34558154 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study 35970781 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional visualized model of impacted tooth
Number of subjects: 41
Study 32085626 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week whole-body vibration (WBV) training
Number of subjects: 90
Study 32085626 — intervention group
Group type: COMPARATOR
Intervention: Placebo group performing the same protocol without vibration
Number of subjects: 90
Study 35088617 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant-driven group education plus standard information
Number of subjects: 138
Study 35088617 — intervention group
Group type: COMPARATOR
Intervention: Standard information alone
Number of subjects: 138
Study 33310533 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive antiepileptic treatment (Vigabatrin preferred for patients younger than two years old)
Number of subjects: 61
Study 33310533 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG monitoring (including video EEG)
Number of subjects: 61
Study 33310533 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin for focal and generalized seizures
Number of subjects: 61
Study 32365090 — intervention group
Group type: EXPERIMENTAL
Intervention: ggmix (general penalized linear mixed model)
Number of subjects: 0
Study 32365090 — intervention group
Group type: COMPARATOR
Intervention: Two-stage approach
Number of subjects: 0
Study 32365090 — intervention group
Group type: COMPARATOR
Intervention: Principal component adjustment
Number of subjects: 0
Study 33599984 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 740
Study 33599984 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel implant
Number of subjects: 740
Study 33599984 — intervention group
Group type: COMPARATOR
Intervention: OCP
Number of subjects: 740
Study 32449907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 35
Study 36262968 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhus coriaria (3 pills daily for 6 days)
Number of subjects: 22
Study 36262968 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone (oral paste, 3 times a day for 6 days)
Number of subjects: 22
Study 34014258 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation with music
Number of subjects: 104
Study 34014258 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation with noise
Number of subjects: 104
Study 34014258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient noise insulation with masking earplugs
Number of subjects: 104
Study 34014258 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 104
Study 32607084 — intervention group
Group type: EXPERIMENTAL
Intervention: Kratom
Number of subjects: 26
Study 32607084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 32579051 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (four, 15‐s straight‐leg raise static stretches)
Number of subjects: 15
Study 32579051 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 15
Study 33487031 — intervention group
Group type: EXPERIMENTAL
Intervention: LHW-led physical activity counselling program (8-week, once weekly)
Number of subjects: 49
Study 32204895 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Ketogenic (VLCK) diet
Number of subjects: 46
Study 32204895 — intervention group
Group type: COMPARATOR
Intervention: Standard Low-Calorie (LC) diet
Number of subjects: 46
Study 35110313 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioural therapy with virtual reality exposure (CBT-in virtuo)
Number of subjects: 302
Study 35110313 — intervention group
Group type: COMPARATOR
Intervention: Group cognitive behavioural therapy with in vivo exposure (CBT-in vivo)
Number of subjects: 302
Study 34798604 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg oral for 21 days)
Number of subjects: 78
Study 34798604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 34798604 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 78
Study 32635650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness exercises, self-monitoring, and mood tracking
Number of subjects: 143
Study 34154926 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with trastuzumab/pertuzumab and docetaxel (mBC)
Number of subjects: 73
Study 34154926 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab/T-DM1 (mBC)
Number of subjects: 73
Study 34154926 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with trastuzumab/pertuzumab or T-DM1 (eBC)
Number of subjects: 73
Study 34154926 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab/pertuzumab (eBC)
Number of subjects: 73
Study 34154926 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 (eBC)
Number of subjects: 73
Study 33450164 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ocular reproxalap (0.1% ophthalmic solution, 0.5% ophthalmic solution, and 0.5% lipid ophthalmic solution)
Number of subjects: 51
Study 32800304 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Dysmorphic Disorder (BDD) group
Number of subjects: 94
Study 32800304 — intervention group
Group type: COMPARATOR
Intervention: Nonpsychiatric controls
Number of subjects: 94
Study 34561362 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioniko
Number of subjects: 7
Study 34561362 — intervention group
Group type: EXPERIMENTAL
Intervention: Kitaro
Number of subjects: 7
Study 34561362 — intervention group
Group type: EXPERIMENTAL
Intervention: SimulEYE
Number of subjects: 7
Study 35372979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor 30 mg twice daily for 26 weeks
Number of subjects: 564
Study 35372979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564
Study 35372979 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor
Number of subjects: 564
Study 35372979 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer carbonate
Number of subjects: 564
Study 33462955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0
Study 33462955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0
Study 33462955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0
Study 33462955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35974290 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks (Q2W)
Number of subjects: 527
Study 35974290 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 300 mg every 4 weeks (Q4W)
Number of subjects: 527
Study 35974290 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of statins with alirocumab
Number of subjects: 527
Study 33639516 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki treatment
Number of subjects: 48
Study 33639516 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 48